# Medical Question & Answer

**Sample ID**: 35bca647-6f61-454f-856d-75dd4ed0cb59
**Dataset Index**: 3209

---

## Question

Una paciente de 24 años de edad acude al cuarto de urgencias de un hospital general por dolor
en fosa ilíaca derecha progresivo de 1 día de evolución que en las últimas horas se acompaña de
vómitos. El abdomen es doloroso, tiene defensa y rebote. Se sospecha de apendicitis pero una
ecografía demuestra una tumoración de ovario derecho de 8 cm de predominio ecogénico ´por lo
que se consulta a ginecología. Se confirma la tumoración y por las características ecográficas se
sospecha de un tumor maligno de células germinales. El manejo que corresponde
a. A. Dar analgésicos y completar estudios
b. Proceder con histerectomía, anexectomía bilateral, omentectomía y linfadenectomía
c. Cirugía de urgencia para remover el tumor ¿?
d. Referir a un centro especializado de cáncer

---

## Answer

> Let's see… What do we have here? The user is asking which management option is most appropriate for a 24-year-old woman with suspected malignant ovarian germ cell tumor presenting with acute right iliac fossa pain, vomiting, and peritoneal signs, and how to prioritize among analgesia with further studies, radical surgery (hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy), urgent surgery to remove the tumor, or transfer to a specialized cancer center. Let's break this down step-by-step. First, I need to think about the clinical urgency and whether there is an acute abdomen requiring immediate operative intervention. Then, I should verify the likely diagnosis and the implications of malignant germ cell tumor biology for surgical strategy. Next, I will review guideline-based surgical principles, especially fertility-sparing surgery and staging. After that, I need to check the role and timing of imaging and tumor markers. Finally, I will weigh each answer choice against evidence and outline the correct course of action with contingencies for torsion or rupture.

> Let me first confirm the clinical urgency. The presence of progressive right lower quadrant pain with vomiting and peritoneal signs (guarding/rebound) raises concern for acute abdomen, and in a young woman with an 8 cm adnexal mass, I need to consider torsion, rupture, or appendicitis as immediate threats, any of which would necessitate urgent surgical exploration rather than deferral or simple analgesia [^111ihp57] [^1161KEtB].

> Hold on, let's not jump to conclusions; I should verify the working diagnosis. The ultrasound suggesting a large, predominantly echogenic right ovarian mass in a 24-year-old strongly suggests a malignant germ cell tumor, which are the predominant ovarian malignancies in adolescents and young adults and are highly chemosensitive, supporting a strategy of fertility-sparing surgery rather than radical hysterectomy with bilateral oophorectomy in this age group [^111XJdNR] [^111iAJf4].

> Next, I should review surgical principles specific to malignant ovarian germ cell tumors. Wait, let me verify the standard of care: conservative, fertility-sparing surgery with removal of the involved adnexa and comprehensive surgical staging is recommended even in advanced disease because of exquisite chemosensitivity; cystectomy should be avoided to prevent spill, and wedge biopsy of a normal contralateral ovary is not recommended because it can impair fertility without benefit [^111iAJf4] [^1153XXq8].

> I need to ensure staging and adjuvant therapy implications are addressed. Comprehensive staging with peritoneal washings, omentectomy, and nodal assessment up to the renal vessels is advised in adults to accurately classify disease and guide postoperative management; however, in clinically apparent early-stage malignant germ cell tumors in pediatric/adolescent and young adult patients, omission of formal nodal dissection may be acceptable per pediatric literature, balancing morbidity and oncologic needs [^1165QGDJ] [^1153XXq8].

> Let me consider the immediate operative plan. Given peritoneal signs and a large solid mass, urgent exploratory surgery is indicated to address torsion, rupture, or bleeding risk and to obtain definitive pathology; a laparoscopic approach is feasible in experienced hands for large adnexal masses in adolescents and young adults, with the key goals being intact removal of the affected adnexa, avoidance of capsule violation, and prompt staging to avoid delaying chemotherapy if indicated [^111ihp57] [^1118iVzw] [^111iAJf4].

> I should double-check the role of preoperative imaging and markers. While contrast-enhanced abdominopelvic CT and chest imaging are standard for staging epithelial ovarian cancer and can refine extent of disease, they should not delay urgent surgery in an acute abdomen; tumor markers (AFP, β-hCG, LDH) should be obtained when feasible but should not postpone emergent operative management in this scenario [^112uDdF5] [^111ihp57].

> Now, I will examine each answer choice against the evidence. Option A, giving analgesics and completing studies, is inadequate because it delays definitive surgical management of an acute abdomen with a suspected malignant mass and risks progression or complications; this contradicts the principle of timely surgical exploration in suspected torsion/rupture and the need for tissue diagnosis and staging in suspected germ cell malignancy [^111ihp57] [^1118iVzw]. Option B, proceeding with hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy, is overly radical for a 24-year-old with a chemosensitive germ cell tumor; fertility-sparing surgery is the standard unless fertility is not desired, and even then, comprehensive staging rather than routine hysterectomy and bilateral oophorectomy is advised in this non-epithelial histology [^1118iVzw] [^111iAJf4]. Option C, urgent surgery to remove the tumor, aligns with the need for emergent operative management, but I should specify that this should be fertility-sparing unilateral salpingo-oophorectomy with comprehensive staging rather than a vague "remove the tumor", and that cystectomy should be avoided to prevent spillage and upstaging [^1118iVzw] [^111iAJf4]. Option D, referring to a specialized cancer center, is reasonable in non-emergent settings, but transfer would be unsafe here given the acute abdomen and risk of torsion/rupture; definitive surgery should proceed locally if a gynecologic oncologist is available, with transfer only if expertise is unavailable and the patient is stabilized [^111ihp57] [^111MAaV2].

> Hmm, wait a minute, I initially thought "complete staging" always mandates full pelvic and para-aortic lymphadenectomy to the renal vessels in all adults; let me reconsider in light of contemporary guidance. While adult practice historically emphasized comprehensive nodal dissection, more recent European and pediatric–young adult guidance allows selective omission of formal lymphadenectomy in clinically apparent early-stage malignant germ cell tumors, particularly in adolescents and young adults, to reduce morbidity without compromising outcomes; thus, the safest, most evidence-aligned plan here is urgent fertility-sparing surgery with staging tailored to intraoperative findings and institutional expertise, rather than a blanket radical approach [^1165QGDJ] [^1153XXq8].

> Putting this together, the best answer is C, but I should be precise: proceed with urgent surgery employing fertility-sparing unilateral salpingo-oophorectomy with comprehensive surgical staging, avoid cystectomy to prevent spill, and do not delay for extensive preoperative imaging or transfer unless absolutely necessary; obtain tumor markers and arrange postoperative management per germ cell pathways, including surveillance or BEP chemotherapy based on final histology and stage [^1118iVzw] [^111iAJf4] [^113hifCp] [^111ihp57].

---

La opción correcta es **cirugía de urgencia para remover el tumor** [^112ua3S4] con resección conservadora (anexectomía unilateral con preservación de útero y ovario contralateral) [^1153XXq8] si la paciente desea fertilidad, ya que los tumores de células germinales en mujeres jóvenes son altamente sensibles a la quimioterapia y tienen excelente pronóstico con tratamiento oportuno y adecuado [^111XJdNR] [^111iAJf4]. La histerectomía y anexectomía bilateral (opción B) **no están indicadas en mujeres jóvenes con deseo de fertilidad** [^1118iVzw]. La opción A retrasa el tratamiento definitivo y la opción D no es apropiada en una urgencia quirúrgica [^111ihp57].

---

## Justificación clínica de la opción C

La cirugía de urgencia para remover el tumor con resección conservadora es el **manejo estándar** para tumores de células germinales en mujeres jóvenes con deseo de fertilidad [^1118iVzw] [^111iAJf4]. Esta estrategia permite:

- **Preservar la fertilidad**: La anexectomía unilateral con preservación del útero y el ovario contralateral es la opción recomendada para mantener la función reproductiva futura [^1118iVzw] [^1153XXq8].

- **Alta sensibilidad a la quimioterapia**: Los tumores de células germinales responden muy bien a la quimioterapia basada en platino (BEP), con tasas de curación superiores al 85% incluso en estadios avanzados [^111XJdNR] [^111iAJf4].

- **Pronóstico favorable**: El diagnóstico y tratamiento oportuno en centros especializados mejoran significativamente el pronóstico y la calidad de vida de las pacientes [^1169BRo6].

---

## Rechazo de las otras opciones

- **Opción A (analgesia y estudios completos)**: Retrasar la cirugía en una paciente con dolor abdominal severo y signos de irritación peritoneal puede complicar el cuadro clínico y aumentar el riesgo de complicaciones quirúrgicas [^111ihp57].

- **Opción B (histerectomía y anexectomía bilateral)**: Esta opción es demasiado radical para una paciente joven con deseo de fertilidad y no está justificada en tumores de células germinales, especialmente en estadios tempranos [^1118iVzw] [^1153XXq8].

- **Opción D (referir a un centro especializado)**: Aunque el manejo en centros especializados es beneficioso, en una urgencia quirúrgica como esta, el tratamiento inmediato en el hospital actual es prioritario para evitar complicaciones [^111ihp57].

---

## Conclusión y recomendación

La opción correcta es **cirugía de urgencia para remover el tumor** con resección conservadora (anexectomía unilateral con preservación de útero y ovario contralateral) [^1118iVzw] [^1153XXq8], seguida de quimioterapia según el estadio y la histología del tumor [^113hifCp]. Este enfoque permite un tratamiento oportuno y eficaz, preservando la fertilidad y mejorando el pronóstico de la paciente [^111XJdNR] [^111iAJf4].

---

## References

### Malignant germ cell tumors of the ovary: clinical and imaging features [^117BMbtq]. Radiologic Clinics of North America (2023). Medium credibility.

Ovarian malignant germ cell tumors are a diverse set of masses originating from the primitive gonadal germ cells, often in young females. They have useful imaging and clinical features, including serum tumor marker elevation, that may aid the radiologist at the time of diagnosis, and also during follow-up. Accurate and timely diagnosis is essential, as standard-of-care therapies lead to a high rate of cancer remission.

---

### Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome [^114gJBGu]. European Journal of Endocrinology (2023). High credibility.

Síndrome de ovario poliquístico (SOP) 2023 international evidence-based guideline — scope, methods, and key outputs are as follows: The guideline targets consistent, evidence-based care and includes 254 recomendaciones y puntos de práctica, and the earlier 2018 guideline is now used in 196 países. Development followed AGREEII and GRADE methodology with broad engagement spanning 71 países; over 12 meses the process addressed 59 preguntas clínicas priorizadas that included 52 revisiones sistemáticas y 3 narrativas. The technical evidence report comprised 6000 páginas supporting 77 recomendaciones basadas en evidencia and 54 recomendaciones de consenso, con 123 puntos de práctica. Key updates include refined individual diagnostic criteria with un algoritmo de diagnóstico simplificado and la inclusión de los niveles de la hormona anti-Mulleriana (AMH) como alternativa al ultrasonido en adultos.

---

### Cancer of the ovary, fallopian tube, and peritoneum: 2021 update [^1143xcBP]. International Journal of Gynaecology and Obstetrics (2021). Medium credibility.

12 MANAGEMENT OF GERM CELL MALIGNANCIES

This group of ovarian tumors consists of a variety of histologically different subtypes that are all derived from the primitive germ cells of the embryonic gonad. Malignant germ cell tumors represent a relatively small proportion of all ovarian tumors. Prior to advances in chemotherapy, the prognosis for these aggressive tumors was poor. The use of platinum‐based chemotherapeutic regimes has made germ cell malignancies among the most highly curable cancers.

12.1 Presentation

These are most common ovarian tumors in the second and third decades of life. They are frequently diagnosed by finding a palpable abdominal mass in a young woman who complains of abdominal pain. The following are the symptoms of germ cell tumors in order of frequency:
Acute abdominal pain.
Chronic abdominal pain.
Asymptomatic abdominal mass.
Abnormal vaginal bleeding.
Abdominal distention.

12.2 Histologic classification

The classification of germ cell tumors of the ovary is important to determine prognosis and for treatment with chemotherapy. Germ cell tumors are classified as follows,:
Dysgerminoma.
Embryonal carcinoma
Teratoma (immature, mature, mature with carcinoma [squamous cell, carcinoid, neuroectodermal, malignant struma, etc]).
Extra‐embryonal differentiation (choriocarcinoma, endodermal sinus tumor [yolk sac tumor]).

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^114xNHVS]. Annals of Oncology (2018). Medium credibility.

Regarding specific circumstances for ovarian cancer, more specifically with respect to patients with non-epithelial OC (follow-up), ESMO 2018 guidelines recommend to obtain regular clinical review with clinical examination, radiological imaging, including abdominopelvic intravaginal ultrasound at regular intervals and monitoring of tumor markers to detect relapse over a period of 10 years, with a gradual increase of the interval between clinical appointments for the close surveillance of patients with early-stage germ cell tumor.

---

### La batalla contra la enfermedad del coronavirus 2019 (COVID-19): manejo de emergencia y control de infecciones en un departamento de radiología [^113PZamX]. Journal of the American College of Radiology (2020). Medium credibility.

Objetivo

Describir las estrategias, manejo de emergencias y los procedimientos de control de infecciones de nuestro departamento durante el brote de la enfermedad por coronavirus 2019 (COVID-19). MéTODOS: Creamos un equipo de manejo de emergencias. El equipo estableció varias medidas: Reconfiguración del flujo de trabajo en el departamento de radiología, distribución de material de protección personal y adiestramiento del personal, procedimientos para la obtención de imágenes en pacientes sospechosos o confirmados con COVID-19, así como para pacientes sin historial de exposición o síntomas. Aquellos con sospecha o confirmación de COVID-19 fueron escaneados en una unidad dedicada para ello.

Resultados

Del 21 de enero del 2020 hasta el 9 de marzo del 2020, 3,083 personas con sospecha o confirmación de COVID-19 recibieron CT de torax. Incluyendo los exámenes iniciales y repetidos, el número total de CT fue 3,340. Como resultado de nuestras medidas de precaución, ninguno de los miembros del personal del departamento de radiología fue infectado con COVID-19. CONCLUSIóN: Las estrategias de planificación y las protecciones adecuadas pueden ayudar a proteger a los pacientes y al personal contra una enfermedad altamente infecciosa. Y a la misma vez ayudar a mantener la capacidad de atender un volumen alto de pacientes.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^111XJdNR]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Malignant germ cell tumors — epidemiology, diagnostic markers, and prognosis: These malignant tumors include dysgerminomas, immature teratomas, embryonal tumors, and endodermal sinus (yolk sac) tumors. They mainly occur in younger individuals who are often diagnosed with stage I disease; the median age at diagnosis is 16 to 20 years. In young individuals (< 35 years) with a pelvic mass, AFP levels can indicate the presence of germ cell tumors, and pregnancy should also be ruled out. Gonadal dysgenesis is a risk factor for germ cell tumors. The recommended workup may include pulmonary function studies if bleomycin is being considered. After appropriate treatment, 5-year survival is more than 85%.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^112RAaaj]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Ovarian cancer — pathology-specific management notes that if analysis of a biopsy or surgical specimen shows a non-epithelial cancer type such as sex cord-stromal or germ cell tumors, a patient should be treated according to separate pathways specific for non-epithelial cancers.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^114hf2aw]. Annals of Oncology (2018). Medium credibility.

Regarding specific circumstances for ovarian cancer, more specifically with respect to patients with non-epithelial OC (surgical resection), ESMO 2018 guidelines recommend to perform debulking surgery in patients with advanced or recurrent granulosa cell tumor.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^1118iVzw]. Annals of Oncology (2018). Medium credibility.

Regarding surgical interventions for non-epithelial ovarian cancer, more specifically with respect to conservative fertility-sparing surgery, ESMO 2018 guidelines recommend to consider performing unilateral salpingo-oophorectomy with preservation of the contralateral ovary and the uterus in patients with germ cell tumor, even in advanced disease because of the sensitivity of the tumor to chemotherapy.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^1153XXq8]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN ovarian cancer — fertility-sparing surgery can be considered for patients with apparent early-stage disease and/or low-risk tumors who wish to preserve fertility using USO (preserving the uterus and contralateral ovary) or BSO (preserving the uterus); consider endometrial sampling to exclude synchronous primary or hyperplasia, refer to reproductive endocrinologist for evaluation and REI consultation as clinically indicated, and note that comprehensive surgical staging should still be performed to rule out occult higher stage disease but may be omitted in pediatric, adolescent, and young adult patients with clinically apparent early-stage malignant germ cell tumors based on the pediatric surgical literature.

---

### Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline [^112uDdF5]. Journal of Clinical Oncology (2016). Medium credibility.

Regarding diagnostic investigations for ovarian cancer, more specifically with respect to imaging for staging, ASCO/SGO 2016 guidelines recommend to obtain a contrast-enhanced (oral and IV) abdominopelvic CT and chest imaging (preferably CT) in the primary clinical evaluation to assess the extent of disease and the feasibility of surgical resection.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^114kWUQC]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN malignant sex cord-stromal tumors — when disease is clinically confined to the ovary with fertility desired, the pathway lists fertility-sparing surgery with complete staging, and lymphadenectomy may be omitted.

---

### ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers [^1137qdVD]. The Lancet: Oncology (2020). High credibility.

The European Society of Gynaecological Oncology and the European Society for Paediatric Oncology jointly developed clinically relevant and evidence-based guidelines for the management of adolescents and young adults aged 15 to 25 years with non-epithelial ovarian cancers, including malignant ovarian germ cell tumours, sex cord-stromal tumours, and small cell carcinoma of the ovary of hypercalcaemic type. The developmental process of these guidelines is based on a systematic literature review and critical appraisal process involving an international multidisciplinary developmental group consisting of experts from relevant disciplines (paediatric oncology, paediatric surgery, medical oncology, pathology, psycho-oncology, gynaecological oncology, and reproductive endocrinology). Given the specific and often complex issues involved in treating this group of patients, fertility sparing surgery and decrease of acute and long-term toxicities from treatment were important criteria for guidelines definition. Prior to publication, the guidelines were reviewed by 54 independent international practitioners in cancer care delivery.

---

### Fertility in women after surgical treatment of nonepithelial ovarian tumors [^11118G3C]. Fertility and Sterility (2010). Low credibility.

Conservative treatment is an acceptable option for women with nonepithelial ovarian tumors who wish to preserve fertility.

---

### Management of ovarian cancer: a 75-year-old woman who has completed treatment [^117Grbxr]. JAMA (2012). Excellent credibility.

Ovarian cancer includes primary tumors of epithelial, sex cord-stromal, or germ cell origin as well as metastatic tumors that frequently originate in the gastrointestinal tract. Approximately 90% of ovarian cancer is epithelial in origin and constitutes a major therapeutic challenge because of its advanced stage of presentation in most patients. Epithelial ovarian cancer is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States, with approximately 1 in 70 women developing this disease in their lifetime. Several important advances in surgical and medical management of this disease have led to prolongation of survival and improvement of quality of life of patients with ovarian cancer. Using the case of Ms W, we discuss the signs, symptoms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgical and postoperative medical management; and present the current recommendations for screening and follow-up.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^117VFtpr]. Annals of Oncology (2018). Medium credibility.

Regarding specific circumstances for ovarian cancer, more specifically with respect to patients with non-epithelial OC (surgical resection), ESMO 2018 guidelines recommend to consider performing fertility-sparing surgery also in patients with advanced stages of germ cell tumor.
Aim to remove as much gross tumor as possible, while avoiding delays in postoperative chemotherapy and long-term morbidity.

---

### Ischiorectal fossa tumors: 30-year single-institution experience [^113gSb1Y]. Diseases of the Colon and Rectum (2024). Medium credibility.

Background

Primary tumors of the ischiorectal fossa are rare and comprise a wide array of pathologies with varying malignant potential. Because of the low prevalence, there is a paucity of data in the literature. This article presents a case series on the management of ischiorectal fossa tumors.

Objective

To present experience from 30 years of managing ischiorectal fossa tumors.

Design

Retrospective single-center analysis.

Settings

A quaternary referral academic health care center.

Patients

All patients treated for ischiorectal fossa tumors were included in the study.

Interventions

All patients underwent surgical management of their disease.

Main Outcome Measures

Disease recurrence and overall survival.

Results

A total of 34 patients (53% women) were identified with a median follow-up of 23 months. Twenty-one patients (62%) were diagnosed with benign and 13 (38%) with malignant tumors. All underwent surgical resection. The median tumor size was 8.4cm. R0 resection was obtained in 28 patients. Twelve patients (35%) developed recurrence (9 after R0 resection) after a median time of 6.5 months. There were no surgical-related mortalities.

Limitations

Limitations to the study include its retrospective nature, single-center experience, and small patient sample size.

Conclusions

Ischiorectal fossa tumors are primarily benign; however, they are associated with high recurrence rates even in the setting of an R0 resection. Treatment should be approached in a multidisciplinary manner, preferably in centers with experience treating these tumors. Close posttreatment surveillance is imperative. See Video Abstract.

Tumores De La Fosa Isquiorrectal Experiencia De Aos En Una Sola Institucin

ANTECEDENTES:Los tumores primarios de la fosa isquiorrectal son raros y comprenden una amplia gama de patologías con potencial maligno variable. Debido a la baja prevalencia, hay escasez de datos en la literatura. Este artículo presenta una serie de casos sobre el tratamiento de los tumores de la fosa isquiorrectal.OBJETIVO:Presentar una experiencia de 30 años en el manejo de tumores de la fosa isquiorrectal.DISEÑO:Análisis retrospectivo de un solo centro. AJUSTES:Un centro de atención médica académico de referencia cuaternaria.PACIENTES:Todos los pacientes tratados por tumores de la fosa isquiorrectal. INTERVENCIONES:Todos los pacientes se sometieron a tratamiento quirúrgico de su enfermedad.PRINCIPALES MEDIDAS DE RESULTADO:Recurrencia de la enfermedad y supervivencia general.RESULTADOS:Se identificaron un total de 34 pacientes (53% mujeres) con una mediana de seguimiento de 23 meses. Veintiún pacientes (62%) fueron diagnosticados con tumores benignos y 13 (38%) con tumores malignos. Todos fueron sometidos a resección quirúrgica. El tamaño medio del tumor fue de 8,4cm. La resección R0 se obtuvo en 28 pacientes. Doce (35%) desarrollaron recurrencia (nueve después de la resección R0) con una mediana de tiempo de 6,5 meses. No hubo mortalidades relacionadas con la cirugía.LIMITACIONES:Las limitaciones del estudio incluyen su naturaleza retrospectiva, experiencia en un solo centro y tamaño pequeño de la muestra de pacientes.CONCLUSIONES:Los tumores de la fosa isquiorrectal son principalmente benignos, sin embargo, se asocian con altas tasas de recurrencia incluso en el contexto de una resección R0. El tratamiento debe abordarse de forma multidisciplinaria y preferentemente en centros con experiencia en el tratamiento de estos tumores. Vigilancia cercana posterior al tratamiento es imperativa. (Traducción-Dr. Aurian Garcia Gonzalez).

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^1147My1A]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN malignant germ cell tumors — surveillance schedule specifies the following frequencies by year: In Year 1 and Year 2, clinical evaluation is Every 3 mo and C/A/P CT is Every 3 mo, with Pelvic USa Every 3 mo and tumor markersb Every 2 mo in Year 1 then Every 3 mo in Year 2. In Year 3, clinical evaluation and Pelvic USa are Every 6 mo, tumor markersb are Every 6 mo, and C/A/P CT is Every 6–12 mo. In Years 4–5, clinical evaluation is Every 12 mo, chest x-ray is Every 6 mo, and C/A/P CT is As clinically indicated. After 5 Years, clinical evaluation is Every 12 mo and chest x-ray and C/A/P CT are As clinically indicated, while tumor markersb are Every 12 mo up to 10 y. Pelvic USa applies only for those with a residual ovary, and all recommendations are category 2A unless otherwise indicated.

---

### Fertility drugs and cancer: a guideline [^114k5zYg]. Fertility and Sterility (2024). High credibility.

Fertility drugs and cancer guideline — methodological limitations in studying associations include inherently higher cancer risk in women who never conceived, risks from infertility-related factors (endometriosis and unopposed estrogens), the low incidence of most cancers, and that cancer diagnosis typically occurs years after fertility drug use. Based on available data, there appears to be no association between fertility medications and breast, colon, or cervical cancer, and there is no conclusive evidence that fertility medications increase uterine cancer risk, although women with infertility have a higher risk of uterine cancer. The guideline states there are insufficient data to comment on melanoma and non-Hodgkin lymphoma risk associated with fertility drug use. Counseling is emphasized: "Se debe informar a las mujeres que puede haber un mayor riesgo de cánceres de ovario invasivos y limítrofes, y cáncer de tiroides asociado con el tratamiento de fertilidad", and it is difficult to determine whether this risk relates to underlying endometriosis, female infertility, or nulliparity.

---

### Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline [^116djP32]. Journal of Clinical Oncology (2016). Medium credibility.

Regarding diagnostic investigations for ovarian cancer, more specifically with respect to imaging for staging, ASCO/SGO 2016 guidelines recommend to decide on ineligibility for medical or surgical cancer treatment after a consultation with a gynecologic oncologist and/or a medical oncologist with gynecologic expertise.

---

### Cancer of the ovary, fallopian tube, and peritoneum: 2025 update [^111iAJf4]. International Journal of Gynaecology and Obstetrics (2025). Medium credibility.

13.3 Diagnosis, staging, and surgical management

Ovarian germ cell tumors are staged similarly to epithelial carcinomas, although the staging system used for male germ cell tumors is probably more useful. The approach to treatment is based on the principles of management of metastatic germ cell tumors of the testis (i.e. low, intermediate, and poor risk). Dysgerminoma is the equivalent of seminoma in testicular cancer. It is exquisitely sensitive to platinum‐based chemotherapy and is radiosensitive. The cure rate is high, irrespective of the stage. The other histological subtypes are equivalent to non‐seminomatous testicular cancers. The aggressiveness of the disease is dependent on the type, with the most aggressive being endodermal sinus and choriocarcinoma; however, with combination chemotherapy, they are highly curable.,

As chemotherapy can cure the majority of patients, even with advanced disease, conservative surgery is standard in all stages of all germ cell tumors. Conservative surgery means laparotomy with careful examination and biopsy of all suspicious areas, with limited cytoreduction, thereby avoiding major morbidity. Fertility‐sparing surgery is considered the standard of care for young patients with early‐stage disease and should also be considered in advanced disease given the high chemosensitivity of the MOGCTs. The choice of approach should be tailored to avoid rupture. Cystectomies should be avoided. The uterus and the contralateral ovary should be left intact. Wedge biopsy of a normal ovary is not recommended as it defeats the purpose of conservative therapy by potentially causing infertility. Even if both ovaries are involved, a partial oophorectomy on one side should be considered. Patients with advanced disease may benefit from 3 to 4 cycles of NACT using the BEP (platinum) regimen with preservation of fertility. Patients who receive conservative surgery with the preservation of one ovary retain acceptable fertility rates despite adjuvant treatment with chemotherapy. There has been no report of higher adverse obstetric outcome or long‐term unfavorable sequelae in the offspring.

Secondary surgery is of no proven benefit except in patients whose primary tumor contained teratomatous elements. Surgical resection of residual masses may be beneficial in such cases, although complete resection is not necessary if the procedure would be too invasive. Mature teratomatous nodules can continue to grow (growing teratoma syndrome) and, more rarely, may undergo malignant transformation over time into an incurable malignancy, such as squamous cell carcinoma.

---

### European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery [^116r1skz]. International Journal of Gynecological Cancer (2017). Medium credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of early-stage disease (surgical excision), ESGO 2017 guidelines recommend to perform total hysterectomy and bilateral salpingo-oophorectomy as the standard of treatment in patients with stage I-II OC. Offer unilateral salpingo-oophorectomy in selected premenopausal patients desiring fertility preservation.

---

### British Gynaecological Cancer Society and British menopause society guidelines: management of menopausal symptoms following treatment of gynaecological cancer [^115FNYT5]. Post Reproductive Health (2024). High credibility.

Regarding specific circumstances for menopause, more specifically with respect to patients with ovarian cancer, BGCS/BMS 2024 guidelines recommend to offer hormone replacement therapy in patients with premature ovarian insufficiency following treatment for germ cell tumors.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^1173R427]. Annals of Oncology (2018). Medium credibility.

Regarding specific circumstances for ovarian cancer, more specifically with respect to patients with non-epithelial OC (hormone therapy), ESMO 2018 guidelines recommend to consider offering hormone replacement therapy in patients with germ cell tumors.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^114aNGUE]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Malignant germ cell tumors — postoperative management by stage and age: After surgery, observation with surveillance is the recommended option for patients with stage I dysgerminoma or stage I, grade 1 immature teratoma based on European and pediatric reports. Observation or chemotherapy may be considered for children or adolescents with select stage IA or IB tumors. For patients with stage II to IV malignant dysgerminomas or immature teratomas, postoperative chemotherapy is recommended.

---

### British Gynaecological Cancer Society and British menopause society guidelines: management of menopausal symptoms following treatment of gynaecological cancer [^1147tn4c]. Post Reproductive Health (2024). High credibility.

Regarding specific circumstances for menopause, more specifically with respect to patients with ovarian cancer, BGCS/BMS 2024 guidelines recommend to recognize that evidence does not demonstrate harm with hormone replacement therapy following treatment for stage I granulosa cell tumors, but counsel patients regarding the uncertainties due to the hormone-sensitive nature of these tumors.

---

### Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline [^114UTfYS]. Journal of Clinical Oncology (2016). Medium credibility.

Regarding diagnostic investigations for ovarian cancer, more specifically with respect to imaging for staging, ASCO/SGO 2016 guidelines recommend to evaluate all patients with suspected stage IIIC or IV invasive epithelial OC by a gynecologic oncologist before initiating therapy to determine the candidacy for primary cytoreductive surgery.

---

### Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion [^116eNiQD]. Fertility and Sterility (2019). High credibility.

Conservative treatments for reproductive malignancies — patients undergoing surgery for cervical, endometrial, or ovarian cancer or borderline tumors of the ovary "may be candidates for conservative surgical approaches or, in the case of endometrial disease, initial medical therapy". "Patients should discuss treatment options with a gynecologic oncologist".

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^113fedrD]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Less common ovarian cancers (LCOC) — included histologies — are listed as Carcinosarcoma (malignant mixed Müllerian tumor [MMMT]); Clear cell carcinoma of the ovary; Mucinous neoplasms of the ovary; Grade 1 endometrioid carcinoma; Low-grade serous carcinoma; Ovarian serous borderline epithelial tumors (low malignant potential [LMP]); Malignant sex cord-stromal tumors; and Malignant germ cell tumors.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^1164pWgA]. Annals of Oncology (2018). Medium credibility.

Regarding specific circumstances for ovarian cancer, more specifically with respect to patients with non-epithelial OC (adjuvant chemotherapy), ESMO 2018 guidelines recommend to offer 3 cycles of a 5-day bleomycin/etoposide/cisplatin regimen in patients with completely resected germ cell tumor and 4 cycles (omit bleomycin to reduce the risk of lung toxicity after the third cycle) in patients with macroscopic residual germ cell tumor.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^115SJKsZ]. Annals of Oncology (2018). Medium credibility.

Regarding specific circumstances for ovarian cancer, more specifically with respect to patients with non-epithelial OC (adjuvant chemotherapy), ESMO 2018 guidelines recommend to consider offering high-dose chemotherapy for durable and prolonged remission in patients with recurrent germ cell tumor.

---

### Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion [^116BNkpU]. Fertility and Sterility (2019). High credibility.

GnRH analog therapy in men — although used during chemotherapy to suppress the hypothalamic-pituitary-gonadal axis in an effort to protect the germinal epithelium, human studies failed to demonstrate fertility preservation or more rapid return of spermatogenesis, and it is, therefore, not appropriate to use in males for fertility preservation.

---

### Cancer of the ovary, fallopian tube, and peritoneum: 2021 update [^115adZAC]. International Journal of Gynaecology and Obstetrics (2021). Medium credibility.

12.3 Diagnosis, staging, and surgical management

Ovarian germ cell tumors are staged similarly to epithelial carcinomas, although the staging system used for male germ cell tumors is probably more useful. The approach to treatment is based on the principles of management of metastatic germ cell tumors of the testis (i.e. low, intermediate, and poor risk). Dysgerminoma is the equivalent of seminoma in testicular cancer. It is exquisitely sensitive to platinum‐based chemotherapy and is radiosensitive. The cure rate is high irrespective of the stage. The other histologic subtypes are equivalent to nonseminomatous testicular cancer. The aggressiveness of the disease is dependent on the type — the most aggressive being endodermal sinus and choriocarcinoma, but with combination chemotherapy, they are highly curable.,

As chemotherapy can cure the majority of patients, even with advanced disease, conservative surgery is standard in all stages of all germ cell tumors. Conservative surgery means laparotomy with careful examination and biopsy of all suspicious areas, with limited cytoreduction, thereby avoiding major morbidity. The uterus and the contralateral ovary should be left intact. Wedge biopsy of a normal ovary is not recommended as it defeats the purpose of conservative therapy by potentially causing infertility. Patients with advanced disease may benefit from 3–4 cycles of neoadjuvant chemotherapy using BEP (bleomycin, etoposide, cisplatin [platinum]) regimen with preservation of fertility. Patients who receive conservative surgery with the preservation of one ovary retain acceptable fertility rates despite adjuvant treatment with chemotherapy. There has been no report of higher adverse obstetric outcome or long‐term unfavorable sequelae in the offspring.

Secondary surgery is of no proven benefit, except in those patients whose tumor was not completely resected at the initial operation and who had teratomatous elements in their primary tumor. Surgical resection of residual masses may be beneficial in such patients, as there may be mature teratomatous nodules that can continue to increase in size (growing teratoma syndrome), and more rarely can undergo malignant transformation over time to an incurable malignancy (e.g. squamous cell carcinoma).

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^113hifCp]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN malignant germ cell tumors — adjuvant treatment by pathologic diagnosis for ovarian/fallopian tube/primary peritoneal cancer: Stage I dysgerminoma or Stage I, grade 1 immature teratoma are managed with Observe Surveillance (LCOC-B). Any stage embryonal tumor, any stage endodermal sinus tumor (yolk sac tumor), Stage II–IV dysgerminoma, Stage I, grade 2 or 3, Stage II–IV immature teratoma, or any stage nongestational choriocarcinoma proceed to Chemotherapyj. Note: All recommendations are category 2A unless otherwise indicated.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^117L39cX]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN malignant germ cell tumors — postoperative pathway for embryonal, endodermal sinus tumor (yolk sac tumor), grade 2–3 immature teratoma, nongestational choriocarcinoma, or mixed histology directs surgery or chemotherapy based on imaging and markers. For "Positive imaging and positive tumor markers", it states "Fertility desired, then fertility-sparing surgery and comprehensive staging; fertility not desired, then completion staging surgery with possible tumor reductive surgery (OV-A) or Chemotherapy (LCOC-13)". When there is "Negative imaging and positive or negative tumor markers", the algorithm directs to "Treatment (LCOC-13)".

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^1168e5Xr]. JCO Global Oncology (2021). High credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of recurrent disease, general principles, ASCO 2021 guidelines recommend to do not offer treatment in patients with tumor marker-positive (CA-125) only recurrent OC.

---

### Tumor chemoconversion following surgery, chemotherapy, and normalization of serum tumor markers in a woman with a mixed type germ cell ovarian tumor [^115SkZAN]. Gynecologic Oncology (2002). Low credibility.

Background

Malignant germ cell tumors of the ovary are often curative after conservative surgery and adjuvant chemotherapy. Persistent tumors despite normalization of serum tumor markers may represent retroconversion to benign masses, but this is rare in ovarian tumors without teratoma elements. The management in such cases has not been defined.

Case

A young woman with a stage IIIC mixed germ cell ovarian tumor containing endodermal and dysgerminoma elements and elevated serum tumor markers underwent conservative surgery followed by chemotherapy. Residual tumor persisted on CT despite the normalization of serum tumor markers. The residual tissue was resected and contained benign tissue.

Conclusions

In cases where masses persist and serum tumor markers normalize, attaining a histological diagnosis, and not chemotherapy, should be considered.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^117Uv1rJ]. Annals of Oncology (2018). Medium credibility.

Regarding surgical interventions for non-epithelial ovarian cancer, more specifically with respect to conservative fertility-sparing surgery, ESMO 2018 guidelines recommend to consider performing conservative surgery in young patients with stage I sex cord-stromal tumor.

---

### Patient-reported work ability during the first two years after rectal cancer diagnosis [^111YuvnF]. Diseases of the Colon and Rectum (2020). Medium credibility.

Background

Rectal cancer treatment is associated with substantial short- and longer-term morbidity that may affect patients' ability to work.

Objective

We evaluated patient-reported work ability during the first 2 years after rectal cancer diagnosis, relative to the Dutch general population. Also, we assessed the association between clinical factors and work ability.

Design

This is a prospective cohort study.

Settings

This study was conducted at the Radiation-Oncology Department of a tertiary center.

Patients

Patients with rectal cancer, < 67 years of age, and treated with curative intent were selected.

Main Outcome Measures

Work ability was assessed with the Work Ability Index before the start of treatment (baseline) and at 3, 6, 12, 18, and 24 months after. The Work Ability Index scores of patients with paid employment were compared with the scores of matched population controls. Mixed models were used to estimate the impact of clinical factors on work ability.

Results

Of the 230 eligible patients, 172 (75%) had paid employment. Work ability decreased at 3 and 6 months compared with baseline. At 12 months, work ability recovered to baseline level but remained significantly lower than in population controls up to 24 months. Fifty-four percent reported 100 to 365 days of sick leave during the first 12 months of treatment versus 2% in the general population. At 24 months, 32% needed substantial adaptations in work activities, worked reduced hours, or were unable to work due to the disease versus 6% in the general population. Female sex, multiple comorbidities, oligometastatic disease, chemoradiation, and abdominoperineal resection were associated with lower work ability.

Limitations

The study was limited by a decrease in questionnaire response rate from 83% to 64% over time.

Conclusions

Patient-reported work ability deteriorates during rectal cancer treatment. Within 24 months after diagnosis, work ability returns to pretreatment level but remains lower than that of the general population. See Video Abstract at http://links.lww.com/DCR/B175. CAPACIDAD DE TRABAJO REPORTADO POR PACIENTES DURANTE LOS PRIMEROS DOS AÑOS DESPUÉS DEL DIAGNÓSTICO DE CÁNCER RECTAL: El tratamiento del cáncer rectal se asocia con una morbilidad significante a corto y largo plazo que puede afectar la capacidad de trabajo de pacientes. Evaluamos la capacidad de trabajo reportado por pacientes durante los primeros dos años después del diagnóstico de cáncer rectal, en relación con la población general holandesa. Además, evaluamos la asociación entre los factores clínicos y capacidad para trabajar. Estudio de cohorte prospectivo. Este estudio se realizó en el Departamento de Radiación Oncológica de en un centro de referencia de tercer nivel. Se seleccionaron pacientes con cáncer rectal, < 67 años de edad, y tratados con intención curativa. La capacidad de trabajo se evaluó con el índice de capacidad de trabajo antes del inicio del tratamiento (línea de base) y a los 3, 6, 12, 18 y 24 meses después. Los puntajes de capacidad laboral de los pacientes con empleo remunerado se compararon con los puntajes de los controles de población pareados. Se utilizaron modelos mixtos para estimar el impacto de los factores clínicos en la capacidad laboral. De los 230 pacientes elegibles, 172 (75%) tenían empleo remunerado. La capacidad de trabajo disminuyó a los 3 y 6 meses en comparación con la línea de base. A los 12 meses, la capacidad de trabajo se recuperó al nivel de referencia, pero se mantuvo significativamente más baja que en los controles de la población hasta 24 meses. Durante los primeros 12 meses, el 54% reportó 100–365 días de baja por enfermedad versus el 2% en la población general. A los 24 meses, el 32% necesitaba adaptaciones sustanciales en las actividades laborales, trabajó horas reducidas o no pudo trabajar debido a la enfermedad frente al 6% en la población general. El sexo femenino, las comorbilidades múltiples, la enfermedad oligometastásica, la quimiorradiación y la resección abdominoperineal se asociaron con una menor capacidad de trabajo. El estudio estuvo limitado por una disminución en la tasa de respuesta al cuestionario del 83% al 64% a lo largo plazo. La capacidad laboral informada por el paciente se deteriora durante el tratamiento del cáncer rectal. Dentro de los 24 meses posteriores al diagnóstico, la capacidad laboral vuelve al nivel de pretratamiento, pero sigue siendo inferior a la de la población general. Consulte Video Resumen en http://links.lww.com/DCR/B175. (Traducción-Dr. Adrian Ortega).

---

### Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002) [^113rDJEC]. British Journal of Cancer (2003). Low credibility.

OBJECTIVES

The objective was to define guidelines for the management of adult patients with carcinomas of unknown primary site. These guidelines are aimed at health professionals treating these patients with the goal of helping to homogenising clinical practice.

The principal questions addressed in this document are:
What pathological diagnostic strategies should be used for each localisation?
To what extent should the primary site be searched for, and what are the limits for this strategy?
What are the prognostic factors?
What treatment strategies should be used for each anatomoclinical type?

---

### Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline [^11118vHk]. Journal of Clinical Oncology (2016). Medium credibility.

Regarding diagnostic investigations for ovarian cancer, more specifically with respect to imaging for staging, ASCO/SGO 2016 guidelines recommend to consider obtaining additional radiographic imaging (such as 18F-FDG-PET or diffusion-weighted MRI) or laparoscopic evaluation to refine the primary evaluation.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^1145Sa8h]. JCO Global Oncology (2021). High credibility.

Diagnosis workup for patients with symptoms of an ovarian mass — imaging includes a combination of transabdominal, pelvic, and transvaginal ultrasound, with contrast-enhanced CT of abdomen and pelvis (with or without chest); clinicians may add MRI.

---

### Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours-a randomised controlled trial of RMI / RCOG vs simple rules [^117BZWx6]. British Journal of Cancer (2017). Low credibility.

In recent years, there has been an increase in the number of women diagnosed with asymptomatic adnexal tumours. This is mainly due to liberal use of modern high-resolution abdominal and pelvic imaging such as ultrasound, MRI and CT. The diagnosis of an adnexal tumour often causes concern to women and health professionals due to perceived difficulties in distinguishing between benign and malignant ovarian tumours.

The best survival rates for patients with ovarian cancer are achieved when treatment is organised and carried out by gynaecological oncologists who work in cancer centres. However, women with asymptomatic benign tumours can be managed expectantly or by minimally invasive surgery. These procedures can be safely undertaken by general gynaecologists in their local hospitals. Achieving the right balance between the desire to treat all ovarian cancers effectively and without delay against the need to avoid unnecessary interventions in women with benign and clinically insignificant lesions is particularly important in postmenopausal women. They are more likely to have age–related, co-morbid conditions such as cardiac or pulmonary disease or diabetes mellitus that increase their risk of surgical and anaesthetic complications. They are also more likely to have had previous abdominal operations increasing further their risk of surgical complications.

---

### Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective [^115Ueae6]. EClinicalMedicine (2024). Medium credibility.

Conclusion

Ovarian IT is a rare and complex disorder and patients present to multiple clinical specialties across both paediatric and adult practice. Careful local multidisciplinary discussion is required in each and every case, both at initial presentation and again at any recurrence(s), to ensure considered and optimal management is delivered. Whilst surgery remains the mainstay of therapy, both at initial presentation and recurrence, there are some very select scenarios where consideration of 1–2 cycles of chemotherapy to assess response may be reasonable. Given the rarity of this entity, discussion with GCT experts, and/or expert national advisory panels, with relevant surgical, oncological, and pathological experience, where available, is recommended for such rare and complex patients.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^112wdTmg]. JCO Global Oncology (2021). High credibility.

Presentation and screening context across resource settings notes that ovarian cancer is often diagnosed at an advanced stage, stage III or IV, and that all women are at risk for ovarian cancer with higher-than-population risk among women with genetic predisposition; personal or family history of breast, ovarian, or colon cancer; infertility; and advancing age. There is currently no reliable screening method or primary prevention available for ovarian cancer in any setting; therefore, most women with ovarian cancer are diagnosed on the basis of symptomatic presentation with the majority at advanced stages across all resource settings. In basic settings, chest x-ray and abdominal ultrasound are typically the only imaging modalities available, and women with ovarian cancer report nonspecific symptoms that may be overlooked or misdiagnosed by primary care providers and contribute to delay in diagnosis.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^1119Kwwx]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Histologic subtypes — epithelial ovarian cancer has four main subtypes (serous, endometrioid, mucinous, clear cell), with most patients (about 70%) having serous cancers; serous tumors can be categorized as low grade (grade 1) or high grade (grade 2 or 3), and ovarian cancer can be divided into Types 1 and 2 based on molecular alterations. Ovarian borderline epithelial tumors (also called LMP tumors or atypical proliferative tumors) are another type of primary epithelial lesion; recent CAP protocols do not use "LMP", and microscopic evaluation shows no evidence of frank invasion by the tumor nodules, with borderline tumors typically serous or mucinous. Carcinosarcomas of Müllerian origin (MMMTs) are biphasic with malignant epithelial and sarcomatous elements, and clonality studies suggest a metaplastic carcinoma with an epithelial precursor and sarcomatous component from transdifferentiation. Non-epithelial subtypes include germ cell tumors (dysgerminomas, immature teratomas, embryonal tumors, endodermal sinus/yolk sac tumors) and malignant sex cord-stromal tumors, which are rare and include granulosa cell tumors (most common) and Sertoli-Leydig cell tumors.

---

### Advanced vulvar cancers: what are the best options for treatment? [^114GmXPt]. Current Oncology Reports (2016). Low credibility.

The treatment of patients with vulvar cancer remains challenging for gynecologic oncologists. Up to 30% of the cases are diagnosed in a clinical condition of irresectability, and some kind of strategy has to be taken into account beyond surgery. In this regard, a common and standard definition is critical to maximize oncological results and minimize complications after treatments. Each patient treatment must be tailored individually according to their clinical and biological features and to the setting in which they are dealing with.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^112Bp5Cj]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Ovarian cancer — subtype focus and less common ovarian cancers: In the NCCN Guidelines, most recommendations are based on data from the most common subtypes — high-grade serous and grade 2/3 endometrioid — and the Guidelines also include recommendations for less common ovarian cancers (LCOC), which include carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors.

---

### Primary and secondary tumors of the peritoneum: key imaging features and differential diagnosis with surgical and pathological correlation [^116Xoc4P]. Insights Into Imaging (2023). Medium credibility.

Peritoneal malignancies represent a diagnostic challenge for abdominal radiologists, oncologists, surgeons and pathologists in multidisciplinary teams, who must address their differential diagnosis, staging and treatment. In this article, we explain the pathophysiology of these processes and lay out the role of different imaging techniques in their evaluation. Then, we review the clinical and epidemiological aspects, the main radiological features and the therapeutic approaches for each primary and secondary peritoneal neoplasm, with surgical and pathological correlation. We further describe other rare peritoneal tumors of uncertain origin and a variety of entities that may mimic peritoneal malignancy. Finally, we summarize the key imaging findings of each peritoneal neoplasm to facilitate an accurate differential diagnosis that may impact patient management. Clinical relevance statementImaging plays an essential role in the evaluation of peritoneal malignancies, assessing their extension, detecting unfavorable sites of involvement and facilitating an accurate differential diagnosis, helping to choose the best therapeutic approach.

---

### Adnexal torsion in adolescents: ACOG committee opinion No, 783 [^1161KEtB]. Obstetrics and Gynecology (2019). High credibility.

Regarding specific circumstances for adnexal torsion, more specifically with respect to adolescent patients (management), ACOG 2019 guidelines recommend to perform minimally invasive surgery with detorsion and preservation of the adnexal structures regardless of the appearance of the ovary.

---

### Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old female [^115mjh5u]. Pediatric Blood & Cancer (2019). Medium credibility.

Growing teratoma syndrome (GTS) is a condition in which mature teratoma with negative tumor markers arises at the site of a treated malignant germ cell tumor. Pathogenic variants in PTEN have been reported to cause autosomal dominant cancer predisposition syndromes and are associated with germ cell tumors. We report the association of a novel heterozygous pathogenic variant in PTEN and very early onset ovarian germ cell tumor complicated by GTS as well as overgrowth syndrome. This marks the youngest reported patient to have developed GTS following treatment of her primary malignant ovarian germ cell tumor.

---

### Laparoscopic treatment of mixed malignant ovarian germ cell tumor in a 16-year-old female adolescent [^112ua3S4]. Journal of Pediatric and Adolescent Gynecology (2016). Low credibility.

Background

Malignant ovarian germ cell tumors are rare entities, although they account for a large proportion of ovarian masses in young women. These tumors have traditionally been removed via laparotomy, because of their large size and solid nature. The use of laparoscopy for treatment of adnexal masses in adolescents has been heavily debated and poorly studied to date.

Case

A 16-year-old female patient presented with abdominal pain and an 11-cm adnexal mass on ultrasound. An emergent laparoscopic salpingo-oophorectomy was performed without complication. Pathology revealed a mixed malignant ovarian germ cell tumor.

Summary and Conclusion

Laparoscopic fertility-sparing surgery offers many benefits over laparotomy, and should be considered in cases of young women with large adnexal masses, even if potential for malignancy exists.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^112YaBGe]. Annals of Oncology (2018). Medium credibility.

Regarding medical management for non-epithelial ovarian cancer, more specifically with respect to general principles, ESMO 2018 guidelines recommend to offer a multimodal treatment approach including chemotherapy
, radical surgery
, high-dose chemotherapy
and radiotherapy in patients with all stages of small cell carcinoma of the ovary, hypercalcemic type.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^1167KWCC]. JCO Global Oncology (2021). High credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of early-stage disease, intraoperative staging, ASCO 2021 guidelines recommend to perform surgical staging by trained surgeons, where feasible, in patients with presumed early-stage OC.

---

### Executive summary of the ovarian cancer evidence review conference [^112X6DEo]. Obstetrics and Gynecology (2023). Medium credibility.

Appendix 6, summarizes studies and society guidelines for patients with an incidental finding of an ovarian cyst on imaging using various methods, including transvaginal ultrasonography, biomarkers, biomarker assays, and multimodal risk assessment, to exclude ovarian cancer. The studies had a number of limitations, including being conducted in patients who underwent surgery, limiting understanding of how the strategies perform in expectantly managed patients. The study populations also frequently had a higher ovarian cancer incidence than expected, which may overestimate diagnostic accuracy.CA 125 is the most frequently measured serum marker for the evaluation and early diagnosis of ovarian cancer despite variation in its measured sensitivity (61–90%) and specificity (71–93%). Sensitivity and specificity are poorer in premenopausal patients than postmenopausal patients, likely because benign conditions that can cause CA 125 elevation occur more frequently in premenopausal patients than postmenopausal patients and the ovarian cancer incidence is lower in premenopausal patients than in postmenopausal patients. The International Ovarian Tumour Analysis Phase 5 study was a prospective, multicenter cohort study with patients selected for surgery or conservative management on the basis of morphology and symptoms. In this study, 1,919 patients with a new diagnosis of a mass that was assessed as benign on ultrasonography had outcomes examined at 24 months after enrollment. Of these, 20.2% had spontaneous resolution of their mass during follow-up, and 16.1% had surgical intervention. The risk of a missed diagnosis at surgery was less than 0.5% when defined as a final diagnosis of invasive malignancy, borderline tumor, torsion, or cyst rupture. We found no prospective studies to guide the frequency or duration of ultrasound surveillance.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^114MyYuL]. JCO Global Oncology (2021). High credibility.

Referral and pathology — confirmation and level of care: The clinical presentation and imaging findings of both benign and other malignancies may be similar or mimic those of ovarian cancer, and patients in basic-resource settings, when feasible, should be referred to a higher-level care center with capacity for surgical and medical management of patients when there is a concern for malignancy; consequently, a histopathologic diagnosis should be undertaken prior to definitive treatment, with referral for diagnosis if feasible, and histology or cytology diagnosis of epithelial ovarian cancer (EOC) should be made by a certified pathologist.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^116AGyMS]. Annals of Oncology (2018). Medium credibility.

Regarding medical management for non-epithelial ovarian cancer, more specifically with respect to adjuvant chemotherapy (indications), ESMO 2018 guidelines recommend to consider offering high-dose chemotherapy for durable and prolonged remission in patients with recurrent germ cell tumor.

---

### Contemporary management of ovarian germ cell tumors and remaining controversies [^116JXZ9d]. Gynecologic Oncology (2020). Medium credibility.

Ovarian germ cell tumors (GCTs) are rare in adults, but are more common in adolescents and young adults. Contemporary management of ovarian GCTs is evolving as collaboration among pediatric, medical, and gynecologic oncologists increases, and studies increasingly incorporate female adult patients. Despite an improved understanding of ovarian GCT, many questions remain. Areas of continued controversy include which stage I ovarian GCTs and immature teratomas can be observed without adjuvant therapy, appropriate risk classification for ovarian GCT, surveillance strategies, and optimal therapy for recurrence. These topics as well as active areas of clinical investigation are discussed.

---

### Malignant mixed ovarian germ cell tumor with embryonal component [^11126Z5A]. Journal of Pediatric and Adolescent Gynecology (2011). Low credibility.

Background

Malignant germ cell tumors of the ovary are relatively rare, making up less than 10% of all ovarian cancers. However, although they represent only a small fraction of ovarian cancers overall, they frequently affect adolescent women of reproductive age, making fertility sparing treatment of paramount importance. Malignant germ cell tumors are subdivided into dysgerminoma and nondygerminomatous tumors. The most common types of nondysgerminomatous tumors are yolk sac and immature teratoma. Mixed germ cell tumors with embryonal carcinoma, nongestational choriocarcinoma, and polyembryoma are less common. Embryonal carcinomas, though rare, are one of the most malignant cancers arising in the ovary.

Case

A 19-year-old female with abdominal pain and massive ascites was found to have a malignant mixed ovarian germ cell tumor with a large embryonal component which was treated via surgical resection and chemotherapy.

Conclusions

Malignant germ cell tumors frequently affect adolescent women of reproductive age. Management of these tumors requires consideration of fertility sparing surgical techniques and chemotherapy management. Using these techniques, the vast majority of patients will maintain their ovarian function and the ability to bear children after their recovery.

---

### Cancer of the ovary, fallopian tube, and peritoneum: 2025 update [^11334xsT]. International Journal of Gynaecology and Obstetrics (2025). Medium credibility.

13 MANAGEMENT OF GERM CELL MALIGNANCIES

This group of ovarian tumors consists of a variety of histologically different subtypes that are all derived from the primitive germ cells of the embryonic gonad. Malignant ovarian germ cell tumors (MOGCTs) represent a relatively small proportion of all ovarian tumors. Before advances in chemotherapy, the prognosis for these aggressive tumors was poor. The use of platinum‐based chemotherapeutic regimes has made germ cell malignancies among the most highly curable cancers.

13.1 Presentation

These are the most common ovarian tumors in the second and third decades of life. They are frequently diagnosed by finding a palpable abdominal mass in a young woman who complains of abdominal pain. The following are the symptoms of germ cell tumors in order of frequency:acute abdominal pain, chronic abdominal pain, asymptomatic abdominal mass, abnormal vaginal bleeding, and abdominal distention.

13.2 Histological classification

The classification of ovarian germ cell tumors is important to determine prognosis and for treatment with chemotherapy. Germ cell tumors are classified below. Histological diagnosis may be difficult and immunohistochemical markers can be valuable and have been added here in parenthesis: dysgerminoma (OCT3/4, PLAP, D2‐40, NANOG, CD117), embryonal carcinoma (OCT3/4, CD30, NANOG, SOX10), teratoma (immature, mature, mature with carcinoma [squamous cell, carcinoid, neuroectodermal, malignant struma, etc.]) (SALL4 commonly positive in all MOGCTs including immature teratomas). Extra‐embryonal differentiation is as follows: non‐gestational choriocarcinoma (b‐hCG, inhibin), and endodermal sinus tumor (or yolk sac tumor) (AFP, glypican‐2 typically; PLAP can be positive).

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^114zixPp]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Pediatric/adolescent malignant germ cell tumors — presentations that may consider observation or chemotherapy: Pediatric/adolescent patients with the following clinical presentations may consider observation or chemotherapy as treatment options — stage IA, IB dysgerminoma; stage IA, grade 1 immature teratoma; stage IA embryonal carcinomas; or stage IA yolk sac tumors — and consultation with a pediatric oncologist for pediatric/adolescent patients is recommended.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^115K2y3r]. Annals of Oncology (2018). Medium credibility.

Regarding medical management for non-epithelial ovarian cancer, more specifically with respect to general principles, ESMO 2018 guidelines recommend to attempt treating patients with small cell carcinoma of the ovary, hypercalcemic type in a more homogeneous way through national and international networks.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^11721D5e]. Annals of Oncology (2018). Medium credibility.

Regarding surgical interventions for non-epithelial ovarian cancer, more specifically with respect to conservative fertility-sparing surgery, ESMO 2018 guidelines recommend to consider performing fertility-sparing surgery also in patients with advanced stages of germ cell tumor.
Aim to remove as much gross tumor as possible, while avoiding delays in postoperative chemotherapy and long-term morbidity.

---

### Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective [^113L4d3c]. EClinicalMedicine (2024). Medium credibility.

Outstanding questions

Further clinical and biological research is required to better understand and resolve current areas of controversy, and how some patients may optimally be managed, including identifying those who, for example, may safely undergo surveillance rather than chemotherapy strategies.

---

### Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective [^1165QGDJ]. EClinicalMedicine (2024). Medium credibility.

The MaGIC expert consensus group opinion is that initial management is surgical, with further treatment dependent on the surgical findings. There are important differences in the approach to surgical staging between adult and paediatric surgeons. Tumours can be large at diagnosis, but importantly, tumour size does not influence staging or prognosis. The tumour-node-metastasis (TNM)and International Federation of Obstetrics and Gynecology (FIGO)staging systems are the most widely used for epithelial (e.g. carcinoma) and non-epithelial (e.g. GCT/IT) ovarian malignancies in adult patients. International guidelines for adult staging of epithelial cancer require intact removal of the affected ovary and ipsilateral fallopian tube with consideration of fertility-sparing surgery (preserving the contralateral ovary and fallopian tube, and the uterus) in selected patients. There is agreement that for patients of reproductive age with malignant OGCT, fertility-sparing surgery is appropriate. In addition, adult guidelines require a complete exploration of the abdomino-pelvic peritoneal cavity, peritoneal washings, peritoneal biopsies (pelvic peritoneum, paracolic gutters, diaphragm) and omentectomy (as least infracolic), along with removal of the pelvic and para-aortic lymph nodes up to the renal vessels bilaterally, although more recently European adult practice guidelines regarding such lymph node excision have been relaxed (see below).

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^114VRdL7]. JCO Global Oncology (2021). High credibility.

Epithelial ovarian cancer (EOC) diagnostic strategies in resource-constrained settings recommend that general practitioners should perform a clinical assessment and family history and, where available, aid diagnosis by ultrasound (abdominal and transvaginal ultrasound, Doppler-enhanced) AND/OR contrast-enhanced computed tomography (CT) of abdomen and pelvis (with or without thorax). In postmenopausal women with symptoms of ovarian cancer, cancer antigen 125 (CA-125) value can assist in diagnosis, ovarian cancer is diagnosed with histologic confirmation in all settings, and CT-guided biopsy or laparoscopy (with sufficient resources) is preferred instead of laparotomy to obtain histologic confirmation prior to any systemic therapy.

---

### Growing teratoma syndrome vs chemotherapeutic retroconversion: case report and review of the literature [^111TtnuG]. Gynecologic Oncology (2004). Low credibility.

Background

Immature ovarian teratoma is the third most common germ cell tumor (GCT) following dysgerminoma and endodermal sinus tumor. The treatment of choice during childbearing age for immature teratoma composes of unilateral oophorectomy and in case of metastatic disease postoperative chemotherapy (BEP). Finding a solid mass in the peritoneal or chest cavity during routine follow up raises the suspicion of distance recurrence. DiSaia was the first to describe the appearance of benign distant metastasis during routine follow up. He termed this phenomenon "chemotherapeutic retroconversion". Latter, Logothetis described what seems to be a similar phenomenon in testicular non-seminomatous germ cell tumor (NSGCT) that he called the "growing teratoma syndrome".

Case

We present a case of a 12-year-old girl treated for growing teratoma syndrome after primary ovarian GCT.

Conclusion

Review of the literature shows that this syndrome and the "chemotherapeutic retroconversion" are probably the same phenomenon.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^11459z8d]. JCO Global Oncology (2021). High credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of recurrent disease, general principles, ASCO 2021 guidelines recommend to offer early palliative care interventions in all patients with OC.

---

### Occult primary, version 3.2014 [^114YrtbQ]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

NCCN Occult Primary — Retroperitoneal mass in adenocarcinoma or carcinoma not otherwise specified: If Histology consistent with germ cell tumor, treat as poor-risk germ cell tumor per NCCN Guidelines for Testicular Cancer or germ cell tumor per NCCN Guidelines for Ovarian Cancer; if Non-germ cell histology, options are Surgery and/or RTo and Consider systemic therapy for selected patientsm.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^114EFVJW]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

WHO histologic classification — ovarian, fallopian tube, and primary peritoneal entities are categorized with behavior codes, where Behavior is coded 0 for benign tumors; 1 for unspecified, borderline, or uncertain behavior; 2 for carcinoma in situ and grade III intraepithelial neoplasia; 3 for malignant tumors, primary site. Sex cord-stromal tumors include Pure Sex Cord Tumors such as Adult granulosa cell tumor of the ovary 3, Granulosa cell tumor, juvenile 1, Sertoli cell tumor NOS 1, and Sex cord tumor with annular tubules 1, and Mixed Sex Cord-Stromal Tumors where Sertoli-Leydig cell tumor, poorly differentiated 3 contrasts with Sertoli-Leydig cell tumor, retiform 1 and Sex cord tumor NOS 1; Pure Stromal Tumors list Steroid cell tumor NOS 0, Steroid cell tumor, malignant 3, and Fibrosarcoma NOS 3. Germ cell tumors include Teratoma, benign 0, Immature teratoma NOS 3, Dysgerminoma 3, Yolk sac tumor NOS 3, Embryonal carcinoma NOS 3, Choriocarcinoma NOS 3, and Mixed germ cell tumor 3; Monodermal Teratoma & Somatic-type Tumors from Dermoid Cyst include Struma ovarii, NOS 0, Struma ovarii, malignant 3, Strumal carcinoid 1, Teratoma with malignant transformation 3, and Cystic teratoma NOS 0. Germ Cell- Sex Cord-Stromal Tumors include Gonadoblastoma 1 and Mixed germ cell- sex cord-stromal tumor, NOS 1; Miscellaneous Tumors include Adenoma of rete ovarii 0, Adenocarcinoma of rete ovarii 3, Wolffian tumor 1, Solid pseudopapillary tumor of ovary 1, Small cell carcinoma, hypercalcemic type 3, Small cell carcinoma, large cell variant 3, and Wilms tumor 3. Tumor-like Lesions listed as benign include Follicle cyst 0, Corpus luteum cyst 0, Stromal hyperplasia and hyperthecosis 0, and Leydig cell hyperplasia 0. Note: All recommendations are category 2A unless otherwise indicated.

---

### ESR essentials: gynaecological causes of acute pelvic pain in women: a primer for emergent evaluation-practice recommendations by the European society of emergency radiology [^111ihp57]. European Radiology (2025). Medium credibility.

Adnexal torsion

Adnexal torsion can involve the ovary, fallopian tube, or (most commonly) both. Isolated fallopian tube torsion spares the ovary, is rare, usually occurs during reproductive years and seldom post-menopause. Clinically, patients present with nausea, vomiting and excruciating unilateral APP.

A normal ovary rarely undergoes torsion, except occasionally in perimenarchal girls or pregnancy. In up to 90% of cases, an underlying ovarian mass serves as the lead point for torsion, particularly if larger than 5 cm. Malignant ovarian tumours and endometriotic cysts are less likely to cause ovarian torsion due to adhesions. Other risk factors include ovulation induction, pregnancy, previous tubal ligation and hypermobility of adnexal structures.

Ovarian torsion is a surgical emergency. Delayed treatment increases the risk of vascular compromise and haemorrhagic infarction. Torsion occurs when the ovary twists on its vascular pedicle, resulting in partial to complete obstruction of arterial inflow and venous outflow.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^113mtbZ9]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN Ovarian Cancer — scope and 5% rule: The guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum and include recommendations for epithelial subtypes — serous, endometrioid, carcinosarcoma (malignant mixed Müllerian tumors [MMMTs] of the ovary), clear cell, mucinous, and borderline epithelial tumors (also known as low malignant potential [LMP] tumors) — with recommendations primarily based on data from high-grade serous and grade 2 and 3 endometrioid carcinoma; they also include recommendations for less common ovarian cancers (LCOC) including carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous carcinoma, grade 1 endometrioid carcinoma, borderline epithelial tumors, and non-epithelial subtypes including malignant sex cord-stromal tumors and germ cell tumors, and a 5% rule (omitting clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^111FV1jU]. JCO Global Oncology (2021). High credibility.

Imaging — ultrasound-based evaluation and feature rules: Women who are postmenopausal with recurrent and persistent symptoms, even in the setting of a negative physical examination, require further evaluation with pelvic ultrasound (transabdominal and transvaginal ultrasound) and referral to a higher-level center for further evaluation including a CT scan, and where resources allow, ultrasound-based imaging including a pelvic ultrasound is a general first step in the diagnostic evaluation. The diagnostic evaluation for an ovarian mass is most widely performed with a pelvic ultrasound; prospective studies from the International Ovarian Tumor Analysis group have identified 10 characteristics of benign versus malignant ovarian mass, and evaluation of these features via pelvic ultrasound with the designation of benign, malignant, or inconclusive, in addition to clinical assessment, provides a general practitioner guidance for a referral to treatment; a mass is classified as probable malignant if at least one malignant feature and none of the benign features are present and vice versa, and if no benign or malignant features are present or if both benign and malignant features are present, then the rules are considered inconclusive (unclassifiable mass), and clinicians should use further clinical and diagnostic testing.

---

### Brief report: a second primary endodermal sinus tumor 9 Years after initial diagnosis [^1177TCvd]. Journal of Pediatric and Adolescent Gynecology (2017). Low credibility.

Background

Ovarian yolk sac tumors (YSTs) are rare malignant germ cell tumors known to present unilaterally, allowing for fertility-sparing surgical treatment with adjuvant chemotherapy. The few published cases of bilateral ovarian involvement were at the time of original diagnosis in patients with widely metastatic disease. We present, to our knowledge, the first case of bilateral ovarian YSTs, diagnosed several years apart, and discuss the implications on recurrence and tumor marker surveillance for these tumors.

Case

This is a case of a young woman who re-presented 9 years after initial treatment, with a YST in the contralateral ovary.

Summary and Conclusions

YSTs are well established as unilateral tumors, however, in rare cases such as this, they might reappear years later on the contralateral ovary.

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^116mRFiz]. Annals of Oncology (2018). Medium credibility.

Regarding medical management for non-epithelial ovarian cancer, more specifically with respect to adjuvant chemotherapy (regimens), ESMO 2018 guidelines recommend to offer 3 cycles of a 5-day bleomycin/etoposide/cisplatin regimen in patients with completely resected germ cell tumor and 4 cycles (omit bleomycin to reduce the risk of lung toxicity after the third cycle) in patients with macroscopic residual germ cell tumor.

---

### European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery [^1147L9t8]. International Journal of Gynecological Cancer (2017). Medium credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of early-stage disease, intraoperative staging, ESGO 2017 guidelines recommend to perform laparoscopic restaging by a gynecologic oncologist with adequate expertise to obtain a comprehensive assessment.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^11329b9P]. JCO Global Oncology (2021). High credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of early-stage disease, adjuvant chemotherapy, ASCO 2021 guidelines recommend to consider offering appropriate evidence-based intraperitoneal chemotherapy, following optimal debulking, only in enhanced settings, highly selected cases in the presence of resources and expertise to manage toxicities.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^111546ui]. JCO Global Oncology (2021). High credibility.

Adjuvant/systemic therapy for stage IV who have received surgery and no chemotherapy — The chart specifies No role for targeted therapy.

---

### Successful pregnancy after conservative surgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: a case report [^117QNZkh]. Gynecologic Oncology (2006). Low credibility.

Background

In invasive ovarian cancer, fertility saving surgery is confined to early-stage and low-grade disease, and only few study reported sparing fertility up to FIGO stage IC ovarian cancer.

Case

We present a rare case of a 30-year-old woman affected by IC ovarian cancer with borderline tumor on controlateral ovary who underwent "conservative" debulking surgery followed by adjuvant chemotherapy. A spontaneous planned pregnancy occurred 5 years postsurgery. At 60-month follow-up, patients have no evidence of disease.

Conclusions

Nowadays, preservation of ovarian function in women with tumors in early stage should be evaluated for conservative surgery. It is important to emphasize that patients selected for conservative surgery should have complete surgical staging. Careful follow-up is mandatory to ensure safety of this procedure.

---

### Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [^113LLM2T]. Annals of Oncology (2023). High credibility.

Regarding classification and risk stratification for ovarian cancer, more specifically with respect to staging, ESMO 2023 guidelines recommend to use the revised 2014 FIGO classification system for staging epithelial OC.

---

### Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary [^114BG5Sf]. Annals of Surgery (2008). Low credibility.

Background

The management of malignant germ cell tumors of the ovary (OMGCT) requires multidisciplinary expertise. We analyze the surgical and medical outcomes of a cohort of patients treated for OMGCT.

Patients and Methods

Data concerning diagnosis, surgery, and medical decisions were reviewed for all patients seen for postoperative management of OMGCT at the Centre Léon Bérard in Lyon and the Institut Curie in Paris between 1985 and 2003. Sixty patients aged 0.4 to 27.9 years (mean 12.8 years) at diagnosis were included.

Results

Twenty (53%) of 38 the International Federation of Gynecology and Obstetrics (FIGO) stage I tumors were staged Ix. All stage Ix tumors had been operated by a nongynecologic surgeon. Relapses occurred in 8 of 24 stage I tumors that were observed (0/8 stage Ia; 5/13 stage Ix (P = 0.044) and 3/3 stage Ic) versus 0/14 stage I treated by adjuvant chemotherapy (P = 0.0015). The risk of relapse was significantly increased if patients underwent postsurgical observation ((HR) = 4.5 (95% CI, 1.5 to 13.3)), and when the tumor contained yolk sac tumor (HR = 7.3 (95% CI, 2.3 to 22.7)). There was no significant prognostic value for age, stage, level of tumor markers at diagnosis, type of surgery, and type of chemotherapy. Five-year overall survival was 96.7%, and event free survival was 83.3%.

Conclusion

Comprehensive staging after removal of localized OMGCT is crucial. It allows a safe observation strategy in stage Ia tumors. Patients with stages Ix and Ic tumors may benefit from adjuvant chemotherapy.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^111MAaV2]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

NCCN malignant germ cell tumors — initial surgery management lists fertility-sparing surgery for those desiring fertility and complete staging for those not desiring fertility, with pathway links to treatment pages; recommendations are framed as category 2A and include evaluation by a gynecologic oncologist. Specifically, the algorithm shows "Fertility-sparing surgery and comprehensive staging (OV-A)" for fertility desired, "Complete staging surgery (OV-A)" for fertility not desired, and directs to "Treatment (LCOC-13)", while noting "All recommendations are category 2A unless otherwise indicated" and "Standard recommendation includes a patient evaluation by a gynecologic oncologist".

---

### Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [^112cnuPQ]. Annals of Oncology (2023). High credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of early-stage disease, intraoperative staging, ESMO 2023 guidelines recommend to perform surgical staging in patients with presumed early-stage OC for classification and deciding optimal systemic therapy.

---

### Gynecologic oncologists and ovarian cancer treatment: avenues for improved survival [^1169BRo6]. Journal of Women's Health (2011). Low credibility.

Ovarian cancer is the deadliest gynecologic malignancy in the United States. Evidence-based interventions for the prevention and early detection of ovarian cancer do not currently exist. However, several treatment guidelines, including the receipt of treatment from a gynecologic oncologist, have been shown to result in improved survival from ovarian cancer.

---

### Growing teratoma syndrome: first case report in a 4-year-old girl [^116UtbvR]. Journal of Pediatric and Adolescent Gynecology (2015). Low credibility.

Growing teratoma syndrome (GTS) consists of germ cell tumors that grow following chemotherapy despite complete eradication of the malignant cells. They can metastasize to any site, particularly the retroperitoneum, mediastinum and cervical region. It typically affects young adults and adolescents. Here we describe the youngest case reported in a 4-year-old girl with an ovarian mixed germ cell tumor who underwent an oophorectomy. Her tumor markers normalized by the end of her chemotherapeutic treatment; however, she developed a retroperitoneal mass that was subsequently resected. Histopathology revealed a mature teratoma, consisting of a GTS. We stress the need for early recognition and treatment of GTS to avoid the subsequent morbidity and mortality associated with it. Although GTS has an excellent prognosis when completely resected, it is essential that the patient be regularly followed-up with serum tumor markers and imaging.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^114RnUM2]. JCO Global Oncology (2021). High credibility.

Regarding medical management for ovarian cancer, more specifically with respect to management of recurrent disease, general principles, ASCO 2021 guidelines recommend to consider offering maintenance systemic therapies in enhanced settings only.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^1129ZCP7]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

American Joint Committee on Cancer (AJCC) TNM and FIGO staging — primary tumor (T1) for ovarian, fallopian tube, and primary peritoneal cancer defines T1 (FIGO I) as "Tumor limited to ovaries (one or both) or fallopian tube(s)", with T1a (FIGO IA) described as "Tumor limited to one ovary (capsule intact) or fallopian tube, no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings" and T1b (FIGO IB) as "Tumor limited to both ovaries; (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings". T1c (FIGO IC) is "Tumor limited to one or both ovaries or fallopian tubes, with any of the following:" where T1c1 (FIGO IC1) is "Surgical spill", T1c2 (FIGO IC2) is "Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface", and T1c3 (FIGO IC3) is "Malignant cells in ascites or peritoneal washings".

---

### Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^111i4crQ]. Annals of Oncology (2018). Medium credibility.

Regarding medical management for non-epithelial ovarian cancer, more specifically with respect to hormone replacement therapy, ESMO 2018 guidelines recommend to consider offering hormone replacement therapy in patients with germ cell tumors.

---

### Imaging of pediatric ovarian tumors: a COG diagnostic imaging committee / SPR oncology committee white paper [^111b5B5s]. Pediatric Blood & Cancer (2023). Medium credibility.

Ovarian tumors in children are uncommon. Like those arising in the adult population, they may be broadly divided into germ cell, sex cord, and surface epithelium subtypes; however, germ cell tumors comprise the majority of lesions in children, whereas tumors of surface epithelial origin predominate in adults. Diagnostic workup, including the use of imaging, requires an approach that often differs from that required in an adult. This paper offers consensus recommendations for imaging of pediatric patients with a known or suspected primary ovarian malignancy at diagnosis and during follow-up.

---

### Current surgical approach: extracranial malignant germ cell tumors [^112vxqtS]. Pediatric Blood & Cancer (2025). Medium credibility.

Germ cell tumors (GCT) are a complex, heterogeneous collection of tumors that may present in either gonadal or extragonadal sites. They consist of a variety of benign and malignant histologies that can occur at several locations throughout the body. An important component of treatment is surgical resection, and while the key components of resection are site specific, the universal goals of GCT resection include the complete resection of tumor without violating the tumor capsule, while preserving function of surrounding organs, minimizing morbidity, and assessing for regional spread.

---

### Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline [^1135UNv7]. JCO Global Oncology (2021). High credibility.

Adjuvant/systemic therapy for stage II/III who have received surgery and no chemotherapy — The chart specifies No role for intraperitoneal chemotherapy and No role for targeted therapy.

---

### Ovarian germ cell tumour classification: views from the testis [^114iDvxT]. Histopathology (2020). Medium credibility.

The classification of ovarian germ cell tumours has remained unchanged for many years, while there have been considerable changes in the testicular classification. In recent years there has been concern about the overtreatment of clinical stage 1 testicular germ cell tumours with increasing use of surveillance for low-risk disease. We outline here the current classification of germ cell tumours of the ovary with particular regard to treatment and outcome and highlight some areas which may cause confusion, particularly pertaining to immature teratomas and mixed germ cell tumours. We suggest that some minor changes to the classification, evidenced by a recent retrospective series by some of the authors, may lead to less adjuvant chemotherapy for immature teratomas and may obviate the need for the grading of immature teratomas, by aligning with testicular experience in pure post-pubertal teratomas. Adoption of this will require retrospective and prospective re-evaluation, but may avoid long-term patient morbidity.

---

### International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? [^1112cqp6]. Journal of the National Cancer Institute (2010). Low credibility.

The Role Of Local Treatment

Surgery for Primary Tumor in the Presence of Metastatic Disease

MBC at diagnosis constitutes 3.5%–7% of all new breast cancers; this apparently marginal problem involves about 7000 new patients every year in the United States alone, up to 50% of whom have locally operable (T1–T3) primary tumors. Traditionally, this group of patients was managed primarily with systemic modalities, limiting local treatments to palliative management of uncontrolled local and/or regional disease (in form of so-called "toilette mastectomy" or low-dose radiotherapy).

The biological rationale for removing the primary tumor in case of proven disease dissemination is debatable. Several potential advantages have been proposed. By removing the primary tumor, one of the sources of further metastatic spread is eradicated; this risk of reseeding is more relevant with the current improvements in systemic treatments. Data from animal studies suggest that removal of tumor bulk may restore immunocompetence because the primary tumor seems to modulate the immune system through release of immunosuppressive factors. A reduction in the number of cancer cells may also lead to increased efficacy of systemic therapy by decreasing the risk of emergence of chemoresistant cells and by removal of necrotic tumor tissue poorly accessible to drugs. Debulking surgery has been proven clinically effective in other common solid tumors, such as ovarian, colorectal, gastric, renal cancers, and malignant melanoma.

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^112dg7h3]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Ovarian borderline epithelial tumors — postoperative follow-up is stratified by invasive implants: treatment recommendations after surgery depend on the presence or absence of invasive implants; for patients with invasive implants, the initial approach may include the same chemotherapeutic regimens used for low-grade (grade 1) serous epithelial ovarian cancer or observation (category 3). Patients with no invasive implants may be observed (category 2B) and monitored; patients who chose fertility-sparing surgery should be monitored by US examinations if necessary, and after childbearing is completed, completion surgery should be considered (category 2B).

---

### Adnexal torsion in adolescents: ACOG committee opinion No, 783 [^111qqRrv]. Obstetrics and Gynecology (2019). High credibility.

Regarding specific circumstances for adnexal torsion, more specifically with respect to adolescent patients (management), ACOG 2019 guidelines recommend to do not remove a torsed ovary unless oophorectomy is unavoidable such as if a severely necrotic ovary falls apart.